Payment overview · 2025
General Payments
$123,079.19
165 reported records · 14 companies
Healthcare provider profile · identity verified
John M Lasala, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · SAINT LOUIS, MO · NPI 1982648317
Verified facts
What the public records show
CMS Open Payments records show John M Lasala, MD received $123,079.19 in general payments during 2025 across 165 reported records.
Boston Scientific Corporation accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $36,810.67 | 29.9% | 38 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $30,999.74 | 25.2% | 28 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $21,738.18 | 17.7% | 27 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13,566.92 | 11.0% | 16 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $12,140.15 | 9.9% | 19 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $6,250.00 | 5.1% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $725.36 | 0.6% | 22 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $226.10 | 0.2% | 2 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $168.29 | 0.1% | 3 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $150.00 | 0.1% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $145.28 | 0.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $73.61 | 0.1% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$44.15 | 0.0% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $40.74 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $58,638.75 | 20 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $39,937.50 | 13 |
| Travel and Lodging | $12,339.41 | 38 |
| Compensation for serving as faculty or as a speaker for a medical education program | $6,350.00 | 2 |
| Food and Beverage | $5,813.53 | 92 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $30,999.74 | 28 | 2025 |
Source payment records
|
|||||
| General - Vascular Access Normalized: general vascular access |
Device | Boston Scientific Corporation | $27,457.22 | 21 | 2025 |
Source payment records
|
|||||
| GORE CARDIOFORM ASD Occluder Normalized: gore cardioform asd occluder |
Device | W. L. Gore & Associates, Inc. | $18,815.77 | 14 | 2025 |
Source payment records
|
|||||
| GORE CARDIOFORM Septal Occluder Normalized: gore cardioform septal occluder |
Device | W. L. Gore & Associates, Inc. | $17,962.41 | 12 | 2025 |
Source payment records
|
|||||
| SELUTION SLR PTA Normalized: selution slr pta |
Device | CORDIS US CORP. | $10,594.09 | 7 | 2025 |
Source payment records
|
|||||
| AMPLATZER TALISMAN Normalized: amplatzer talisman |
Device | Abbott Laboratories | $8,591.74 | 8 | 2025 |
Source payment records
|
|||||
| VersaCross Access Solution Normalized: versacross access solution |
Device | Boston Scientific Corporation | $8,125.00 | 2 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $6,250.00 | 2 | 2025 |
Source payment records
|
|||||
| ACCENT Normalized: accent |
Device | Abbott Laboratories | $4,797.87 | 4 | 2025 |
Source payment records
|
|||||
| Product in Development Normalized: product in development |
Device | W. L. Gore & Associates, Inc. | $2,120.00 | 3 | 2025 |
Source payment records
|
|||||
| SELUTION SLR PTCA Normalized: selution slr ptca |
Device | CORDIS US CORP. | $562.36 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $461.00 | 7 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $253.00 | 3 | 2025 |
Source payment records
|
|||||
| AMPLATZER Normalized: amplatzer |
Device | Abbott Laboratories | $177.31 | 4 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| ORSIRO MISSION Normalized: orsiro mission |
Device | BIOTRONIK INC., Teleflex LLC | $143.19 | 2 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $132.35 | 1 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $131.27 | 1 | 2025 |
Source payment records
|
|||||
| General - Atherectomy Normalized: general atherectomy |
Device | Boston Scientific Corporation | $125.73 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $96.31 | 1 | 2025 |
Source payment records
|
|||||
| Eagle Eye Normalized: eagle eye |
Device | Philips North America LLC | $76.10 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $44.15 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $40.74 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.51 | 1 | 2025 |
Source payment records
|
|||||
| General - Ultrasound Normalized: general ultrasound |
Device | Boston Scientific Corporation | $28.79 | 1 | 2025 |
Source payment records
|
|||||
| GUIDELINER Normalized: guideliner |
Device | Teleflex LLC | $4.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $123,079.19 · 165 records | Boston Scientific Corporation | ACCENT, AMPLATZER, AMPLATZER TALISMAN, AVVIGO Guidance System, Coronary Other, Eagle Eye, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, GORE CARDIOFORM ASD Occluder, GORE CARDIOFORM Septal Occluder, GUIDELINER, General - Atherectomy, General - Balloon Catheters, General - Therapies, General - Ultrasound, General - Vascular Access, Indigo System, ORSIRO MISSION, Paradise Ultrasound Renal Denervation System, Product in Development, REPATHA, ROTAPRO, SELUTION SLR PTA, SELUTION SLR PTCA, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, VersaCross Access Solution, WATCHMAN Access System | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error